Active Biotech AB (publ) (ACTI.ST)
Develops experimental drug treatments for cancer and inflammatory eye diseases.
5.20+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-68.2%
The outlook
ACTI.ST is trading near the bottom of its 52-week range and below both its 50- and 200-day moving averages, reflecting a bearish lean from a technical standpoint. The average analyst price target sits roughly 381% above the current price, signaling a substantial gap between current levels and consensus expectations. Overall sentiment remains cautious despite the bullish target backdrop.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +381% vs current price
Market cap
$137.1M
52-wk high
17.46
52-wk low
3.70
50-day avg
5.90
200-day avg
5.46
Trailing P/E
—